Release issued 9th June 2009

Overall market will increase by a modest $300 million from 2008 to 2018, according to a new report from Decision Resources
 
June 9, 2009-Waltham, Mass. - Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's Disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of Parkinson's Disease therapies will increase modestly from $2.5 billion in 2008 to $2.8 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
 
The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the Dopamine agonist drug class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab and UCB/Schwarz Pharma's Neupro. However, sales of some of these agents, including Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab, will be offset by increased uptake of generic equivalents. Market growth will also be constrained by the generic erosion of other key therapies, including Novartis/Orion Pharma's Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck's Agilect/Azilect.
 
According to the report, market sales will also be driven by the emergence of novel agents, most notably Merck Serono/EMD Serono/Newron Pharmaceuticals' safinamide, Solvay Pharmaceuticals' pardoprunox, and Acadia Pharmaceuticals/Biovail Pharmaceuticals' pimavanserin, which will be used to treat niche Parkinson's Disease populations.
 
The report also finds that the results of recent key clinical trials will affect the way clinicians treat patients with early Parkinson's Disease.
 
"The results of the ADAGIO trial demonstrated the disease-modifying effects of Agilect/Azilect, making it more likely that physicians will prescribe this drug to newly-diagnosed Parkinson's Disease patients," said Decision Resources Analyst Sami Fam, Ph.D. "However, the need for a more definitive and robust neuroprotective therapy remains in the indication, and this unmet need is not expected to be fulfilled over the next ten years."

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread